Their findings suggest that augmenting these natural allies within our microbiota could be a viable method to increase the efficacy of checkpoint inhibitors like anti-programmed cell death protein 1 ligand 1 (PD-L1), a popular cancer therapy (Sivan et al., 2015). The gene discussed is CD274; the disease is cancer.